| Age (years) | 41.3 (SD 14.5) | 31.9 (SD 11.2) | 0.02 |
| Gender |
| Female | 4 (28.6) | 16 (44.6) | |
| Male | 10 (71.4) | 20 (55.6) | 0.3 |
| Ethnicity |
| Caucasian | 4 (28.6) | 6 (16.7) | |
| Asian Indian/Pakistani | 2 (14.3) | 11 (30.6) | |
| Asian Chinese | 0 (0) | 2 (5.6) | |
| Asian Other | 1 (7.1) | 5 (13.9) | |
| Asian African | 6 (42.9) | 11 (30.6) | |
| All Other | 1 (7.1) | 1 (2.8) | 0.57 |
| HIV status |
| Positive | 1 (7.1) | 4 (11.1) | |
| Negative | 3 (92.9) | 32 (88.9) | 0.68 |
| Amikacin at any point |
| Yes | 13 (92.9) | 21 (58.3) | |
| No | 1 (7.1) | 15 (41.7) | 0.02 |
| Capreomycin at any point |
| Yes | 2 (14.3) | 15 (41.7) | |
| No | 12 (85.7) | 21 (58.3) | 0.07 |
| Duration of injectable treatment (days) | 123.4 (SD 62.1) | 115.9 (SD 90.2) | 0.77 |
| Total dose of injectable agent (g) | 96.3 (SD 54.7) | 90.7 (SD 63.1) | 0.78 |
| Baseline creatinine (μmol/l) | 85.9 (SD 52.8) | 67.7 (SD 12.9) | 0.07 |
| Creatinine increase >44 from baseline at any point |
| Yes | 5 (35.7) | 2 (6.5) | |
| No | 9 (64.3) | 29 (93.5) | |
| Not known | 0 | 5 | 0.01 |